Interní Med. 2001; 3(4): 161-164

Postižení jater u drogově závislých osob

MUDr. Petr Husa CSc1, MUDr. Libuše Husová2
1 Klinika infekčních chorob, FN Brno
2 III. interní klinika gastroenterologická, FN Brno-Bohunice

Keywords: intravenous drug users, viral hepatitis A,B,C,D,G, treatment of chronic hepatitis C, treatment of HIV and HCV co-infection.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P, Husová L. Postižení jater u drogově závislých osob. Interní Med. 2001;3(4):161-164.

Největší riziko pro játra narkomanů představuje společné sdílení injekčních jehel a stříkaček, které vede k přenosu virových hepatitid. Mezi narkomany se nejčastěji vyskytuje virová hepatitida C. Zřídkavý není ani výskyt virových hepatitid B a G. V některých státech světa má význam i virová hepatitida D, která se však v České republice vyskytuje jen naprosto výjimečně. I v našich podmínkách jsou popsány mezi narkomany epidemie virové hepatitidy A, u kterých se však předpokládá převážně fekálně-orální cesta přenosu infekce.

Liver Injury in Substance Dependent Persons

The major risk for liver injury in intravenous drug users is from a common sharing of needles and syringes, which usually results in transmission of viral hepatitis. Viral hepatitis C is the most frquent type of viral hepatitis among intravenous drug users. Occurrence of viral hepatitis B and G is not scarce as well. In some places of the world viral hepatitis D is quite common to be found, on the contrary in Czech Republic it is considered as an exception. The fecal-oral route of transmission is predominant in viral hepatitis A, but some epidemics of this diseases have been described among intravenous drug users abroad and in our republic as well.

Klinika infekčních chorob, FN Brno

Interní gastroenterologická klinika, FN Brno

Download citation

References

  1. Alter, M.J.: Epidemiology of hepatitis C in the West. Semin. Liver. Dis., 15, 1995, s. 5. Go to original source... Go to PubMed...
  2. Bower, W., Nainan, O.V., Han, X., Margolis, H.S.: Duration of viremia in hepatitis A virus infection. J. Infect. Dis., 182, 2000, č. 1, s. 12-17. Go to original source... Go to PubMed...
  3. Diamantis, I., Bassetti, S., Erb, P. et al.: High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J. Hepatol., 26, 1997, č. 5, s. 794-797. Go to original source... Go to PubMed...
  4. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J. Hepatol., 30, 1999, č. 6, s. 956-961.
  5. Giménez-Barcons, M., Forns, X., Ampurdanés, S. et al.: Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. J. Hepatol., 30, 1999, č. 6, s. 1028-1034. Go to original source... Go to PubMed...
  6. Grosheide, P., Van Damme, P.: Prevention and control of hepatitis B in the community. 2. vydání. Wilrijk, Viral Hepatitis Prevention Board 1996, 63 s.
  7. Helcl, J., Němeček, V., Švandová, E. et al.: Sérologický přehled markerů virové hepatitidy typu A v České republice- 1996. Prakt. Lék., 79, 1999, č. 7, s. 399-402.
  8. Koff, R.S.: Other hepatitis viruses including the hepatitis G virus. In: Wilson, R.A., eds.: Viral Hepatitis. New York, Marcel Dekker, Inc. 1997, s. 259-282.
  9. Lettau, L.A., McCarthy, J.G., Smith, M.H. at al.: Outbreak of severe hepatitis due to delta and hepatitis B virus in parenteral drug abusers and their contacts. N. Engl. J. Med., 317, 1987, s. 1256-1262. Go to original source... Go to PubMed...
  10. Mravčík, V., Šebáková, H., Kania, A.: Séroprevalence virových hepatitid typu A-C u injekčních uživatelů drog. Epidemiol. Mikrobiol., Imunol., 49, 2000, č.1, s. 19-23.
  11. Nishizawa, T., Okamoto, H., Konishi, K. et al. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem. Biophys. Res. Commun., 241, 1997, č. 1, s. 92-97. Go to original source... Go to PubMed...
  12. Silva M.O., Roth, D., Reddy, K.R. et al.: Hepatic dysfunction accompanying acute cocaine intoxication. J. Hepatol., 12, 1991, č. 2, s. 312. Go to original source... Go to PubMed...
  13. Stroffolini, T., Ferrigno, L., Cialdea, L. et al.: Incidence and risk factors of acute Delta hepatitis in Italy: results from a national surveillance system. J. Hepatol., 21, 1994, č. 7, s.1123-1126. Go to original source... Go to PubMed...
  14. Trmal, J., Kellerová, J., Koblížková, R., Krpálková, H., Holasová, J.: Dopad výměnného programu injekčních jehel a stříkaček na šíření virové hepatitidy typu C. Epidemiol. Mikrobiol. Imunol., 48, 1999, 4. 4, s.171-178. Go to original source...
  15. Viral Hepatitis Prevention Board: News. Viral Hepatitis, 4, 1995, č. 1, s. 3-4.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.